GlassScriptPhysician profile
Chelsie Word
NPI 1952672057
$3,613.92
in general payments reported to CMS, 2019-2025
21 companies · $540 in 2025
The $540 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $95.14 · 2022: $379 · 2023: $1,503 · 2024: $1,096 · 2025: $540.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,139.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $632.29 | 2022-2024 | Fasenra, Airsupra, Tezspire |
| Regeneron Healthcare Solutions, INC. | $450.30 | 2022-2025 | Dupixent |
| Genzyme Corporation | $371.49 | 2022-2025 | |
| Csl Behring | $355.23 | 2022-2025 | Hizentra, Privigen, Haegarda |
| Glaxosmithkline, LLC. | $310.61 | 2022-2025 | Nucala |
| Grifols USA, LLC | $301.57 | 2022-2025 | Prolastin-C Liquid, Xembify |
| Genentech USA, INC. | $247.74 | 2022-2025 | Xolair |
| Incyte Corporation | $231.82 | 2022-2025 | Opzelura |
| Amgen INC. | $138.77 | 2022-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $113.11 | 2022-2023 | Hyqvia, Takhzyro |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $95.14 | 2021 | |
| Ars Pharmaceuticals Operations, INC. | $78.34 | 2025 | Neffy |
| Pharming Healthcare, INC. | $56.98 | 2022-2025 | Ruconest |
| Biocryst US Sales Co., LLC | $56.83 | 2022-2024 | Orladeyo |
| Blueprint Medicines Corporation | $46.48 | 2023-2024 | Ayvakit |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $27.33 | 2023 | Stealthstation S8 Platform |
| Mylan Specialty L.P. | $25.40 | 2023 | Yupelri |
| Novartis Pharmaceuticals Corporation | $20.04 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.38 | 2022 | |
| Pfizer INC. | $18.63 | 2022 | |
| Aerin Medical INC. | $16.44 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chelsie Word listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.